Late Treatment With Autologous Expanded Regulatory T Cell Therapy after Alemtuzumab Induction Is Safe and Facilitates Immunosuppression Minimization in Living Donor Renal Transplantation

0
20
Researchers established that delayed autologous Treg therapy was both feasible and safe, even 12 months after cell production. The findings presented a new treatment protocol for Treg therapy, potentially expanding its applications to other indications.
[Transplantation]
Full Article